Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23959177 | 0.82 | NOTUM (0.31) | NOTUMALDH1A1 | |
| SCHEMBL5275276 | 0.81 | GAA (0.31) | — | |
| SCHEMBL5281308 | 0.79 | PDE10A (0.32) | — | |
| SCHEMBL5277206 | 0.78 | MAOB (0.33) | — | |
| SCHEMBL5284998 | 0.76 | — | — | |
| SCHEMBL5279063 | 0.75 | MAOB (0.40) | — | |
| SCHEMBL14369254 | 0.71 | GRIA1 (0.38) | — | |
| SCHEMBL7195827 | 0.71 | ALDH1A1 (0.46) | NOTUMALDH1A1 | |
| SCHEMBL4216684 | 0.71 | — | — | |
| SCHEMBL18506418 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127413-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180093983-A1 | 5H-PYRIDO[3,2-B]INDOLE COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| US-9751879-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9725449-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-17 | — | — | US | disclosed |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-03 | — | — | US | disclosed |
| US-9458156-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093983-A1 | 5H-PYRIDO[3,2-B]INDOLE COMPOUNDS AS ANTICANCER AGENTS | IDO1, IDO2, TPH1 | NOTUM 3304/4885ALDH1A1 509/4885 |
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, TOP2A | NOTUM 1201/4885ALDH1A1 895/4885 |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | NOTUM 1906/4885ALDH1A1 1397/4885 |
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MCL1, TP53, TOP2A | NOTUM 2303/4885ALDH1A1 696/4885 |
| US-20180127413-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, TOP2A | NOTUM 1500/4885ALDH1A1 1049/4885 |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | NOTUM 1906/4885ALDH1A1 1397/4885 |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | NOTUM 1906/4885ALDH1A1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.